The Role of BrightFocus Foundation in the Discovery of Bexarotene's Potential Therapeutic Value
Dr. Gary Landreth: I think the foundation has been extraordinarily important in providing
support for projects that are really focused on fundamental mechanisms there. What the
foundation has done has been incredibly important, particularly for supporting young scientists
and projects which would not garner support yet from the NIH or other agencies.
The contribution of the foundation to the enterprise is absolutely critical. I think
we all in the business, we all think this is one of the most important organizations
that supports the core mission
Dr. Paige Cramer: Cost is associated with these trials, with these phases phase one,
phase two, phase three are astronomically expensive,
Dr. Landreth: This is a very expensive business to use animal models of the disease takes
a lot of money, it takes a lot of time. And since these are models of aging, and we have
to basically work to six months in a year in advance, so the students have to plan their
experiments will then generate the animals long time before they formed the experiments.
The foundation operates at very critical juncture by supporting projects that are higher risk
and generally with Junior investigators who may not have been as competitive at the national
level this niche is really, really important and I and the foundation is absolutely critical
to the national effort in figuring out how this disease works.
Dr. Cramer: It works and that those experiments and those ideas are really what will drive
the field forward. Fortunately for the later lab, Gary has been very much a recipient of
the foundation’s support and that's allowed us to really combat some interesting questions
and some interesting hypotheses and to really, we believe, find new things about the disease
that may be very important later on.